Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02267603 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
A Phase 2 study of Recurrent Merkel Cell Carcinoma and Stage III Merkel Cell Carcinoma AJCC v7, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 13
- Study locations
NCT02267603 is a Phase 2 study of Recurrent Merkel Cell Carcinoma and Stage III Merkel Cell Carcinoma AJCC v7 that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants. The trial reports 13 study locations across 11 states.
The verdict
NCT02267603, a Phase 2 study of Recurrent Merkel Cell Carcinoma and Stage III Merkel Cell Carcinoma AJCC v7, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 13
- Study locations
Study Summary
This phase II trial studies how well pembrolizumab works in treating patients with Merkel cell cancer that cannot be removed by surgery or controlled with treatment, or has spread to other parts of the body. Pembrolizumab may stimulate the immune system to identify and destroy cancer cells.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
Study Locations (13)
California
- Stanford Cancer Institute Palo Alto - Palo Alto
- UCSF Medical Center-Mount Zion - San Francisco
Louisiana
- Louisiana State University Health Science Center - New Orleans
- University Medical Center New Orleans - New Orleans
Connecticut
- Yale University - New Haven
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
New York
- Mount Sinai Hospital - New York
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-11-25 |
| Est. Completion | 2021-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02267603
The ClinicalTrials.gov registry entry for NCT02267603 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Recurrent Merkel Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02267603 reports 13 study locations spanning 11 distinct geographic areas - top geographies include California, Louisiana, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02267603 about?
NCT02267603 is a clinical study titled "Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer". This phase II trial studies how well pembrolizumab works in treating patients with Merkel cell cancer that cannot be removed by surgery or controlled with treatment, or has spread to other parts of the body. Pembrolizumab may stimulate the immune system to identify and destroy cancer cells.
What is the current status of trial NCT02267603?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2014-11-25. Estimated completion is 2021-12-15.
What conditions does trial NCT02267603 study?
This clinical trial studies the following conditions: Recurrent Merkel Cell Carcinoma, Stage III Merkel Cell Carcinoma AJCC v7, Stage IIIA Merkel Cell Carcinoma AJCC v7, Stage IIIB Merkel Cell Carcinoma AJCC v7, Stage IV Merkel Cell Carcinoma AJCC v7.
What interventions are being tested in trial NCT02267603?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02267603?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02267603 being conducted?
This trial has 13 study locations across California, Connecticut, Florida, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Merkel Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Recurrent Merkel Cell Carcinoma
All registered trials for this condition
Stage III Merkel Cell Carcinoma AJCC v7
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.